Palbociclib plus letrozole clinical outcomes PALOMA-2

In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival by 13 months compared to letrozole alone (27.6 vs 14.5 months) with manageable hematologic toxicity and maintained quality of life, but did not demonstrate a significant overall survival benefit after 90 months of follow-up.

Abstract

The PALOMA-2 trial demonstrated that palbociclib plus letrozole significantly improved progression-free survival compared to placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer. Median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), with consistent benefit observed across all patient subgroups including Asian patients (25.7 vs 13.9 months, HR 0.49, P=0.007) and those with low disease burden. Notably, PFS improvement occurred regardless of objective response status, with non-responders experiencing median PFS of 10.9 versus 5.6 months (HR 0.72, P=0.016).

The treatment delayed time to subsequent chemotherapy by approximately 10 months (40.4 vs 29.9 months). However, after 90.1 months of follow-up, median overall survival was 53.9 versus 51.2 months (HR 0.96, P=0.34), showing no significant improvement. The primary toxicity was hematologic, with grade 3-4 neutropenia occurring in 66.4% of patients (vs 1.4% with placebo), increasing to 89.2% in Asian populations. Despite this, febrile neutropenia remained rare (1.8-2.0%), and treatment discontinuation rates were low (9.7-12.2% vs 5.9%). Quality of life was maintained with no significant differences in FACT-Breast Total or EQ-5D scores between treatment arms, and pain scores significantly improved with palbociclib plus letrozole (P=0.0183). Neutropenia did not negatively impact quality of life measures.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: "Palbociclib plus letrozole clinical outcomes PALOMA-2". The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met specific criteria:

• PALOMA-2 Trial Relevance: Related to the PALOMA-2 trial (NCT01740427) or its analyses.
• Patient Population: Included patients with hormone receptor-positive, HER2-negative advanced breast cancer.
• Clinical Outcomes: Reported clinical efficacy or safety outcomes.
• Intervention Specificity: Focused specifically on palbociclib plus letrozole therapy.
• Disease Population Specificity: Focused on appropriate breast cancer populations.
• Study Design Appropriateness: Was a clinical study in humans.

Data extraction

We asked a language model to extract specified data columns from each paper, including:

• Study Type: Phase, design characteristics, primary/secondary publication, focus, follow-up duration.
• Patient Population: Total number of patients, key eligibility criteria, baseline demographics, disease characteristics, prior therapy details.
• Treatment Details: Dosing schedules, treatment duration, discontinuation rates.
• Efficacy Outcomes: PFS, OS, objective response rate, time to subsequent therapy.
• Safety Outcomes: Common adverse events, hematologic toxicities, treatment discontinuations.
• Quality of Life: QOL data from relevant questionnaires.

Results

Characteristics of Included Studies

The included publications derived from the PALOMA-2 trial, a phase 3 randomized controlled trial that enrolled 666 postmenopausal women with ER+/HER2- advanced breast cancer.

Patients were randomized to palbociclib plus letrozole (n=444) or placebo plus letrozole (n=222). Baseline disease characteristics revealed measurable disease in 76-77% of patients, with approximately 48% having visceral disease and 52% non-visceral disease.

Study

Efficacy Outcomes

• Progression-Free Survival: Consistent improvement across analyses with median PFS records.

• Overall Survival: No significant improvement noted after median follow-up.

• Time to Subsequent Therapy: Median times significantly delayed.

Safety Outcomes

• Hematologic Toxicities: Neutropenia was the most common adverse event.

Patient-Reported Outcomes and Quality of Life

Using FACT-Breast and EQ-5D questionnaires, baseline QOL scores were comparable and improvements noted in pain scores with treatment.

Subgroup Analyses

Subgroup analyses indicated benefits were seen across all analyzed groups, notably in low disease burden patients.

Synthesis

The PALOMA-2 trial consistently demonstrated benefits in PFS while overall survival did not reach statistical significance. This discordance between outcomes warrants further exploration. Overall findings emphasize the importance of maintaining quality of life in treatment considerations.